These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 10925733

  • 1. Factors affecting levodopa effects in Parkinson's disease.
    Ogawa N.
    Acta Med Okayama; 2000 Jun; 54(3):95-101. PubMed ID: 10925733
    [Abstract] [Full Text] [Related]

  • 2. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
    LeWitt PA.
    Mov Disord; 2015 Jan; 30(1):64-72. PubMed ID: 25449210
    [Abstract] [Full Text] [Related]

  • 3. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
    Onofrj M, Thomas A, Vingerhoets F, Martin W, Giménez-Roldán S, Azulay JP, Bernhard G, Schmidt W, Markabi S.
    J Neural Transm (Vienna); 2004 Aug; 111(8):1053-63. PubMed ID: 15254793
    [Abstract] [Full Text] [Related]

  • 4. Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.
    Luer MS.
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):169S-79S. PubMed ID: 10555945
    [Abstract] [Full Text] [Related]

  • 5. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
    Melamed E, Zoldan J, Galili-Mosberg R, Ziv I, Djaldetti R.
    J Neural Transm Suppl; 1999 Nov; 56():173-83. PubMed ID: 10370911
    [Abstract] [Full Text] [Related]

  • 6. Abdominal pain: a symptom of levodopa end of dose wearing off in Parkinson's disease.
    Rana AQ, Depradine J.
    West Indian Med J; 2011 Mar; 60(2):223-4. PubMed ID: 21942133
    [Abstract] [Full Text] [Related]

  • 7. Dopamine neurotransmission and treatments for Parkinson's disease in the molecular biology era.
    Ogawa N.
    Eur Neurol; 1997 Mar; 38 Suppl 1():2-5. PubMed ID: 9276193
    [Abstract] [Full Text] [Related]

  • 8. Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off.
    Murata M, Mizusawa H, Yamanouchi H, Kanazawa I.
    J Neural Transm (Vienna); 1996 Mar; 103(10):1177-85. PubMed ID: 9013404
    [Abstract] [Full Text] [Related]

  • 9. [Enzyme inhibitors in Parkinson treatment].
    Gütschow M, Meusel M.
    Pharm Unserer Zeit; 2006 Mar; 35(3):218-25. PubMed ID: 16724525
    [No Abstract] [Full Text] [Related]

  • 10. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.
    Kurth MC.
    Drugs Aging; 1997 May; 10(5):332-40. PubMed ID: 9143854
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease--In relation to the effects of Mucuna pruriens.
    Nagashima Y, Kondo T, Sakata M, Koh J, Ito H.
    J Neurol Sci; 2016 Feb 15; 361():229-34. PubMed ID: 26810548
    [Abstract] [Full Text] [Related]

  • 13. Catechol O-methyltransferase inhibition and the treatment of Parkinson's disease.
    Nutt JG.
    Adv Pharmacol; 1998 Feb 15; 42():331-4. PubMed ID: 9327908
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease.
    Frey KA.
    Ann Neurol; 2001 Mar 15; 49(3):285-7. PubMed ID: 11261500
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The new Parkinson's disease drugs].
    Hasegawa K.
    Nihon Rinsho; 2000 Oct 15; 58(10):2066-71. PubMed ID: 11068448
    [Abstract] [Full Text] [Related]

  • 19. Long-term management of Parkinson's disease using levodopa combinations.
    Müller T, Möhr JD.
    Expert Opin Pharmacother; 2018 Jun 15; 19(9):1003-1011. PubMed ID: 29913079
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.
    Clin Neuropharmacol; 2010 May 15; 33(3):135-41. PubMed ID: 20216409
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.